|
HY-19121A-10mg
|
MedChemexpress LLC
|
TCV-309 (chloride) [CAS 121494-09-5]
|
|
Cancer-programmed cell death
|
|
|
HY-19121A-100mg
|
MedChemexpress LLC
|
TCV-309 (chloride) [CAS 121494-09-5]
|
|
Cancer-programmed cell death
|
|
|
HY-19121A-25mg
|
MedChemexpress LLC
|
TCV-309 (chloride) [CAS 121494-09-5]
|
|
Cancer-programmed cell death
|
|
|
HY-19121A-5mg
|
MedChemexpress LLC
|
TCV-309 (chloride) [CAS 121494-09-5]
|
|
Cancer-programmed cell death
|
|
|
HY-19121A-50mg
|
MedChemexpress LLC
|
TCV-309 (chloride) [CAS 121494-09-5]
|
|
Cancer-programmed cell death
|
|
|
HY-N2503-1mg
|
MedChemexpress LLC
|
Ginsenoside F4 [CAS 181225-33-2]
|
|
COVID-19-immunoregulation
|
|
|
HY-N2503-5mg
|
MedChemexpress LLC
|
Ginsenoside F4 [CAS 181225-33-2]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99175-1mg
|
MedChemexpress LLC
|
KWAR 23 [CAS 2243227-60-1]
|
|
Cancer-programmed cell death
|
|
|
HY-P99175-10mg
|
MedChemexpress LLC
|
KWAR 23 [CAS 2243227-60-1]
|
|
Cancer-programmed cell death
|
|
|
HY-P99175-5mg
|
MedChemexpress LLC
|
KWAR 23 [CAS 2243227-60-1]
|
|
Cancer-programmed cell death
|
|
|
HY-19121A-1mL
|
MedChemexpress LLC
|
TCV-309 (chloride) [CAS 121494-09-5] (10mM in DMSO)
|
|
Cancer-programmed cell death
|
|
|
HY-P80958-10uL
|
MedChemexpress LLC
|
SATB2 Antibody
|
|
|
|
|
HY-P80958-100uL
|
MedChemexpress LLC
|
SATB2 Antibody
|
|
|
|
|
HY-P80958-50uL
|
MedChemexpress LLC
|
SATB2 Antibody
|
|
|
|
|
HY-P80970-10uL
|
MedChemexpress LLC
|
FMRP Antibody
|
|
|
|
|
HY-P80970-100uL
|
MedChemexpress LLC
|
FMRP Antibody
|
|
|
|
|
HY-P80970-50uL
|
MedChemexpress LLC
|
FMRP Antibody
|
|
|
|
|
HY-P80977-10uL
|
MedChemexpress LLC
|
FACL4 Antibody
|
|
|
|
|
HY-P80977-100uL
|
MedChemexpress LLC
|
FACL4 Antibody
|
|
|
|
|
HY-P80977-50uL
|
MedChemexpress LLC
|
FACL4 Antibody
|
|
|
|
